1.Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
Suman S KARANTH ; Anurag GUPTA ; Mukhyaprana PRABHU
Singapore medical journal 2014;55(1):e7-8
Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis. We report the case of a 50-year-old woman who was incidentally detected to have essential thrombocytosis after suffering an episode of cerebrovascular accident with faciobrachial monoparesis. She was subsequently initiated on hydroxyurea. Within seven weeks of therapy, the patient noticed irregular hyperpigmented patches over her feet, hands and perioral region, with bluish-grey longitudinal bands on all 20 nails. Hydroxyurea-induced hyperpigmentation and melanonychia are not commonly reported. To the best of our knowledge, this is only the third published report of hydroxyurea-induced hyperpigmentation and melanonychia involving all 20 nails. Physicians need to be aware of such mucocutaneous side effects to avoid misdiagnosis and unwarranted fear in patients. The decision to discontinue the intake of the drug depends heavily on the future risk of thrombotic events.
Female
;
Humans
;
Hydroxyurea
;
adverse effects
;
therapeutic use
;
Hyperpigmentation
;
chemically induced
;
Middle Aged
;
Nail Diseases
;
chemically induced
;
Nails
;
drug effects
;
Stroke
;
drug therapy
;
Thrombocytosis
;
drug therapy
;
Treatment Outcome
2.Hydroxyurea Induced Perimalleolar Ulcers.
Kavitha SARAVU ; Praveen VELAPPAN ; Naik LAKSHMI ; Barkur Ananthakrishna SHASTRY ; Joseph THOMAS
Journal of Korean Medical Science 2006;21(1):177-179
Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.
Aged
;
Ankle
;
Antineoplastic Agents/adverse effects/therapeutic use
;
Humans
;
Hydroxyurea/*adverse effects/therapeutic use
;
Leg Ulcer/*chemically induced/pathology/therapy
;
Leukemia, Myeloid, Chronic/drug therapy
;
Male
;
Middle Aged
;
Phlebotomy
;
Polycythemia Vera/drug therapy
;
Wound Healing